We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    MNK14274069
Previous Study | Return to List | Next Study

Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis (OPTIONS)

This study is currently recruiting participants.
Verified September 2017 by Mallinckrodt
Sponsor:
ClinicalTrials.gov Identifier:
NCT03126760
First Posted: April 24, 2017
Last Update Posted: September 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Mallinckrodt
  Purpose
This is a multicenter, multiple dose study to estimate the response rate, and examine the safety of H.P. Acthar® Gel (Acthar) in subjects with RRMS who have not responded to high dose steroids. Approximately 66 subjects will be randomized.

Condition Intervention Phase
Relapsing, Remitting Multiple Sclerosis Drug: Repository Corticotropin Injection Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Mallinckrodt:

Primary Outcome Measures:
  • Expanded Disability Status Scale (EDSS) [ Time Frame: Day 42 ]
    Response rate on EDSS for each treatment group

  • Expanded Disability Status Scale (EDSS) [ Time Frame: Day 42 ]
    90% confidence interval (CI) of response rate on EDSS for each treatment group


Secondary Outcome Measures:
  • Multiple Sclerosis Impact Scale Version 1 (MSIS-29) [ Time Frame: Days 7, 14, 21 and 42 ]
    Response rate on MSIS-29 for each treatment group

  • Multiple Sclerosis Impact Scale Version 1 (MSIS-29) [ Time Frame: Days 7, 14, 21 and 42 ]
    90% CI of response rate on MSIS-29 for each treatment group

  • EDSS [ Time Frame: Days 7 and 21 ]
    Response rate on EDSS for each treatment group

  • EDSS [ Time Frame: Days 7 and 21 ]
    90% CI of response rate on EDSS for each treatment group

  • Clinical Global Impression of Improvement Scale (CGI-I) [ Time Frame: Days 7, 21, and 42 ]
    CGI-I mean scores for each treatment group

  • Clinical Global Impression of Improvement Scale (CGI-I) [ Time Frame: Days 7, 21, and 42 ]
    90% CI of mean scores for each treatment group


Estimated Enrollment: 66
Actual Study Start Date: May 22, 2017
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Acthar
Repository Corticotropin Injection 1 mL (80U) subcutaneously administered QD for 14 consecutive days
Drug: Repository Corticotropin Injection
Administered subcutaneously once a day for 14 consecutive days
Other Name: H.P. Acthar® Gel
Placebo Comparator: Placebo
Placebo 1 mL subcutaneously administered QD for 14 consecutive days.
Drug: Placebo
Administered subcutaneously once a day for 14 consecutive days

Detailed Description:
Subjects with RRMS who have experienced a relapse and who will receive 3 to 5 (given over a period of up to 7 days) days of treatment with high dose steroids (oral or IV) within 10 days of the onset of relapse symptoms are candidates for the current study. At 14 (± 1) days following the initiation of high dose steroids, subjects will be re-assessed with the Expanded Disability Status Scale/Functional Systems Score (EDSS/FSS) and subjects who do not improve by at least 1 point on the FSS will be randomized on a 1:1 basis to receive subcutaneous (SC) Acthar 1 mL (80 U) once a day (QD) or SC matching placebo 1 mL QD for 14 days. Follow-up visits then occur at 14, 28 and 42 days.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must have a diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald criteria.
  2. Subjects must have had a relapse with onset ≤25 days prior to the Baseline Visit. Relapse is defined as new neurological symptom(s) persisting for ≥24 hours, and accompanied by an objective change in neurological examination.
  3. Subject must have started treatment with 3 to 5 days of high dose corticosteroids within 10 days of the onset of the first relapse symptom.
  4. Subjects must have an EDSS score of 3.5 to 6.5 (inclusive) at the Baseline Visit.

Exclusion Criteria:

  1. Subject has a history of use of Acthar for the treatment of multiple sclerosis (MS).
  2. Subject has only sensory, bowel/bladder, and/or cognitive symptoms of MS associated with the most recent relapse.
  3. Subject has a history of sensitivity to adrenocorticotropic hormone (ACTH) preparations or to porcine protein products.
  4. Subject has been treated with natalizumab, alemtuzumab, ocrelizumab, daclizumab or any immunosuppressants (including but not limited to cyclophosphamide, mitoxantrone, or rituximab) in the 6 months prior to the Screening Visit or throughout the study.
  5. Subjects receiving any disease modifying treatments (including beta-interferons, glatiramer acetate, fingolimod, teriflunomide, and dimethyl fumarate) must have been on a stable dose(s) for 30 days prior to the Baseline Visit, and plan to remain on that dose(s) throughout the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03126760


Contacts
Contact: Valerie Carvajal 800-556-3314 clinicaltrials@mallinckrodt.com
Contact: Bryan Due, PhD 800-556-3314 clinicaltrials@mallinckrodt.com

Locations
United States, Arizona
Territory Neurology and Research Institute Recruiting
Tucson, Arizona, United States, 85704
United States, Colorado
Advanced Neurosciences Research LLC Recruiting
Fort Collins, Colorado, United States, 80528
United States, Florida
University of South Florida Recruiting
Tampa, Florida, United States, 33612
United States, Georgia
Meridian Clinical Research LLC Recruiting
Savannah, Georgia, United States, 31405
United States, Illinois
Consultants in Neurology LTD Recruiting
Northbrook, Illinois, United States, 60062
United States, Kansas
Department of Neurology, University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
United States, Ohio
The Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
University of Cincinnati Physicians Company, LLC Recruiting
Dayton, Ohio, United States, 45417
United States, Texas
Texas Neurology, PA Recruiting
Dallas, Texas, United States, 75214
Central Texas Neurology Consultants Recruiting
Round Rock, Texas, United States, 78681
Neurology Center of San Antonio Recruiting
San Antonio, Texas, United States, 78258
United States, Utah
Rocky Mountain MS Research Group Recruiting
Salt Lake City, Utah, United States, 84103
United States, Washington
MultiCare Neuroscience Center of WA Recruiting
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Mallinckrodt
Investigators
Study Director: Bryan Due, PhD Mallinckrodt
  More Information

Responsible Party: Mallinckrodt
ClinicalTrials.gov Identifier: NCT03126760     History of Changes
Other Study ID Numbers: MNK14274069
First Submitted: April 4, 2017
First Posted: April 24, 2017
Last Update Posted: September 25, 2017
Last Verified: September 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Adrenocorticotropic Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs